251 results about "Chemo-radiotherapy" patented technology

The invention relates to a natural pharmaceutical composition, a preparation method thereof and an application of the natural pharmaceutical composition in preparation of attenuated synergistic medicaments in cancer radiotherapy and chemotherapy. The natural pharmaceutical composition is prepared from extract obtained by decocting and concentrating ginger and dried orange peel decoction, gingerol, dried orange peel water extract and nobiletin according to the ratios of (3-5):(2-9):(1-6):(2-5). The composition has an excellent effect on treating emesis and other side effects caused by cancer radiotherapy and chemotherapy, and can simultaneously play a role in inhibiting tumors.

The invention provides a medicinal composition for treating digestive system dysfunction. The medicinal composition is characterized by comprising the following components in parts by weight: 10-25 parts of ginseng, 10-25 parts of bighead atractylodes rhizome, and 12-25 parts of poria. The medicinal composition is particularly suitable for treating gastrointestinal dysfunction after radiotherapy or chemotherapy, is good in curative effect, and does not have toxic or side effect; the patients have good tolerance and can easily accept the medicinal composition; the treatment cost is low. The medicinal composition can be used for treating gastrointestinal dysfunction after radiotherapy or chemotherapy independently, and also can be used for treating malignant tumor diseases by combining radiotherapy or chemotherapy.

The invention provides a ginseng ferment and a preparation process thereof. The ginseng ferment comprises the following components by weight ratio: 8 parts of fresh ginsengs, 38 parts of apples, 16 parts of carrots, 3 parts of rhodiola rosea, 5 parts of burdock, 2 parts of gingers, 2.5 parts of mung bean sprouts, 3 parts of mushrooms, 7 parts of cabbages, 5 parts of pea sprouts, 4 parts of wolfberry fruits, 1 part of kelp, 1.5 parts of alfalfa and 4 parts of cucumbers. The ginseng ferment is scientific and reasonable in formula and capable of remaining the activity and the function of an effective constituent to the maximum extent by using a green preparation process and has the functions of ginseng in greatly restoring vitality, tonifying spleen and lung, nourishing fluid and relieving thirst, smoothing the nerves and benefitting intelligence, resisting fatigue and boosting immunity; the ginseng ferment regulates blood fat and blood sugar due to the exertion of the synergistic effect of the ginseng, the rhodiola rosea, the burdock and the wolfberry fruits, and plays effects of cell activation, digestion promotion and comprehensive detoxification and has good prevention and inhibition functions for cancers so as to be a good irreplaceable food therapy product for patients with radiotherapy and chemotheraphy; and in addition, the ginseng ferment can be used for neutralizing redundant radicals in a human body and has the effects of resisting oxidation as well as maintaining beauty and keeping young so as to be a good health care product.

The invention discloses a Chinese medicinal composition for treating malignant tumor, belonging to the field of Chinese medicines. The Chinese medicinal composition is a medicament preparation formed from herba oldenlandiae, astragalus root, tuckahoe, prepared pinellia tuber, herba scutellariae barbatae, teloon, scorpion, scolopendra and the like by adopting advanced processes including extraction with water, extraction with ethanol, enzymolysis of trypsinase and the like according to a certain compatible requirement, and the medicament preparation is preferably prepared into capsules and tablets. The Chinese medicinal composition has a certain function for relieving symptoms for lung cancer, liver cancer, gastric cancer, intestinal cancer, breast cancer, encephaloma, lymph cancer and other malignant tumors, reducing tumor bodies, inhibiting the growth of the tumors and the like; and according to the Chinese medicinal composition, the human immune capability can be improved, the lives of patients suffered from tumors can be prolonged and the adverse reactions of leukocytopenia, dizzy, weakness and fatigue, skinniness, poor appetite, nausea and vomiting and the like due to radiotherapy chemotherapy for cancers can be effectively relieved.

The present invention provides an anticancer auxiliary medicine using 20(S)-protopanaxadiol as effective component and its application. Said medicine possesses the action of raising therapeutic effect of anticancer medicine, reducing toxicity of anticancer medicine, preventing and curing leukopenia due to radiotherapy and chemotherapy and raising immunity of human body, and can be used for auxiliary therapy of carcinoma.

The invention relates to a combination made of 20(R)-ginsenoside taken serving as active constitutent and the application of the combination as medicine or health products. The 20(R)-ginsenoside combination mainly comprises the following weight percentage compositions of the components: 30 percent to 60 percent of 20(R)-ginsenoside Rg3, 10 percent to 40 percent of 20(R)-ginsenoside Rh2 and 10 percent to 30 percent of ginsenoside III, wherein the ginsenoside III is 20(R)-protopanoxadiol-3-O-beta-pyrane xylopyranosyl (1-2) beta-D-pyrane glucosyl (1-2) beta -D-pyrane glucoside. The invention relates to application of the drug combination in preparing anticancer aided drug for preventing and curing leucocyte reduction caused by radiotherapy and chemotherapy and in medicine or health products improving human body immunity.

The invention relates to an anti-cancer sustained release injection containing epothilone derivative, consisting of sustained microspheres and menstruum. The sustained microspheres comprise anti-cancer drugs selected from taxane, alkylating agent and/or plant alkaloid and the like, the epothilone derivative and sustained release auxiliary material. The menstruum is a special menstruum containing suspending agent. The epothilone derivative is selected from epothilone B, epothilone D, iso-epothilone D, BMS-247550, azaepothilone B, furan epothilone D or BMS-310705. The sustained release auxiliary material is selected from poly-dl-lactide, the glycolic acid copolymer of the poly-dl-lactide, polyethyleneglycol, the polylactide copolymer of the polyethyleneglycol, carboxyl terminated polylactide copolymer, fatty acid and decanedioic acid copolymer, etc. The suspending agent is selected from carboxymethyl cellulose and the like with the viscosity of 100cp to 3000cp (under the temperature of 25 DEG C to 30 DEG C). The sustained release microsphere can also be made into a sustained release implant. The sustained release injection is injected or arranged in or around the tumour and can release drug at partial position for 40 days approximately, therefore, the sustained release injection improves the local drug concentration selectively and enhances the treatment effect of non-operative treatments, such as radiotherapy, chemotherapy and the like at the same time.

The invention relates to an anti-cancer sustained release injection containing epothilone derivative, consisting of sustained microspheres and menstruum. The sustained microspheres comprise anti-cancer drugs selected from taxane, alkylating agent and/or plant alkaloid and the like, the epothilone derivative and sustained release auxiliary material. The menstruum is a special menstruum containing suspending agent. The epothilone derivative is selected from epothilone B, epothilone D, iso-epothilone D, BMS-247550, azaepothilone B, furan epothilone D or BMS-310705. The sustained release auxiliary material is selected from poly-dl-lactide, the glycolic acid copolymer of the poly-dl-lactide, polyethyleneglycol, the polylactide copolymer of the polyethyleneglycol, carboxyl terminated polylactide copolymer, fatty acid and decanedioic acid copolymer, etc. The suspending agent is selected from carboxymethyl cellulose and the like with the viscosity of 100cp to 3000cp (under the temperature of 25 DEG C to 30 DEG C). The sustained release microsphere can also be made into a sustained release implant. The sustained release injection is injected or arranged in or around the tumour and can release drug at partial position for 40 days approximately, therefore, the sustained release injection improves the local drug concentration selectively and enhances the treatment effect of non-operative treatments, such as radiotherapy, chemotherapy and the like at the same time.

The objective of the invention is to provide a traditional Chinese medicine granule for treating side effects on an alimentary canal after cancer chemotherapy and a preparation method thereof. The invention is characterized in that the granule is prepared from an active component, a binder and pharmaceutically acceptable adjuvant, and the active component is prepared from the traditional Chinese medicines consisting of 600 to 800 g of milkvetch root, 250 to 350 g of dwarf lilyturf tuber, 150 to 250 g of red ginseng, 150 to 250 g of white atractylodes rhizome fried with bran, 150 to 250 g of Poria cocos, 200 to 300 g of licorice, 200 to 300 g of radix scrophulariae, 200 to 300 g of Chinese angelica, 250 to 350 g of dark plum, 250 to 350 g of prepared pinellia tuber, 200 to 300 g of cablin patchouli herb, 200 to 300 g of dried orange peel and 200 to 300 g of curcuma rhizome. The granule is applicable to cancer patients who vomit or retch because of damage of both qi and yin and rising of stomach qi resulting from damage of the spleen and the stomach by anti-radiogenic cancer and chemotherapy drugs, and the granule can mitigate symptoms like no appetite, tiredness, hypodynamia, a red or light red tongue with little fluid and weak pulse.

The invention relates to a Chinese medicinal decoction for treating leucocytopenia caused by chemotherapy for cancer, and also to the process for preparation, wherein the constituents include (by weigh ratio) root of American ginseng 20g, hairy deerhorn 30g, ganoderma lucidum 20g, astragalus root 30g, fruit of barbary wolf berry 20g, Chinese caterpillar fungus 20g, dry human placenta 20g, aniseed 10g, prepared aconite root 20g, notoginseng 10g, euphoria longan steud 20g, white atractylodes rhizome 10g, Ficus carica 20g, dried rehmannia root 20g, psoralea fruit 10g, aloe 10g, turtle shell 10g, ophiopogon root 10g, ligustrum japonicum 20g, Siberian solomonseal rhizome 10g, broomrape 10g, mongloian snakegourd 10g, root of herbaceous peony 10g, coix seed 10g, cornus officinalis 10g, rhubarb horsetails 5g, cape jasmine 5g, schisandra fruit 10g, licorice root 10g, lily bulb 5g.

The invention discloses a nutriment for improving the immunity of patients suffering from tumors after operation, radiotherapy and chemotherapy and a preparation method of the nutriment, and belongs to the technical field of medical foods. The nutriment comprises 45-98g/L of protein, 22-48g/L of fat, 98-245g/L of carbohydrate, 0-18g/L of dietary fibers, 0.35-0.75g/L of vitamins, 3.6-7.2g/L of trace elements, 1.0-2.2g/L of nucleotide, 0.2-20g/L of arginine, 0-0.2g/L of taurine, and an appropriate amount of water. The nutriment has various nutrient components, is rich in glutamine, arginine, nucleotide, omega-stability fatty acid and the like, is scientific in proportion, improves the nutritional status of patients, improves the resistance power of patients during operation, and after operation, radiotherapy and chemotherapy, improves the immunity of organisms of the patients, controls the acute inflammation, protects the function of intestinal mucosal barrier, reduces complication, shortens hospital days and reduces treatment price.

The invention provides a medicine for adjusting body immunity during chemoradiotherapy period. The medicine can provide body immunity and reduce chemoradiotherapy toxic and side effects. The technical scheme adopted by the invention is as follows: the medicine for adjusting body immunity during chemoradiotherapy period is prepared from the following raw material medicines in parts by weight: 40-60 parts of Astragalus membranaceus, 5-15 parts of Angelica sinensis, 10-30 parts of Radix Ophiopogonis, 1-3 parts of American ginseng, 5-15 parts of dogwood, 5-15 parts of the fruit of Chinese wolfberry, 5-15 parts of radix scrophulariae, 5-10 parts of chrysanthemum, 5-10 parts of flowers carthami, 30-60 parts of Hericium erinaceus, 30-60 parts of Chinese actinidia root, 10-15 parts of Amauro-derma rugosum, 15-25 parts of Semen Cuscutae, 5-15 parts of fructus psoraleae, 15-25 parts of glossy privet fruit, 15-25 parts of eclipta, 15-25 parts of fried Rhizoma Atractylodis Macrocephalae and 15-25 parts of Chinese yam.

A detoxicating synergistic Chinese medicine for radiotherapy or chemicotherapy is prepared from astragalus root, wolfberry fruit and ganoderma. Its advantage is high curative effect.

The invention provides a pharmaceutical composition for treating thrombocytopenia, which comprises gen-seng, epimeddium, radix astragali, angelica sinensis, radix rehmanniae preparata, spatholobus stems, hairyvein agrimony, and tangerine peel. The pharmaceutical composition of the invention can be prepared into clinically-acceptable dosage forms by adding routine auxiliary materials according to routine technology. The pharmaceutical composition of the invention has significant effect on treating thrombocytopenia and leucopenia, promoting proliferation of bone marrow hematopoietic stem cells, repairing damage and injury of bone marrow hematopoietic tissue caused by radiation, preventing marrow inhibition caused by radiotherapy and chemotherapy, or improving symptoms and increasing life quality of tumor patients, and has no side effect.

The invention relates to a natural pharmaceutical composition, a preparation method thereof and an application thereof in preparing an attenuating synergistic medicament in radiotherapy and chemotherapy of cancer. The natural pharmaceutical composition is composed of concentrated extract of decoctions of dried ginger and evodia rutaecarpa, gingerol, evodia rutaecarpa extract and evodiamine in proportion of (1-4):(3-7):(2-9):(2-3). The composition provided by the invention has good curative effects on vomit and the like caused by the side effects of radiotherapy and chemotherapy of cancer, and also plays an effect on inhibiting tumor.

The present invention discloses a suspension composition for treating oral mucositis caused by chemoradiotherapy, and relates to a new drug for treating oral mucositis. The suspension composition comprises: 1, local anesthetics; 2, histamine 1 receptor antagonists; 3, a mucosal repairing agent and a drug dispersing agent; 4, an anti-foaming agent; 5, microcrystalline cellulose; 6, unreactive assistant materials; 7, pure water. The preparation method comprises: 1, preparing a solution I; 2, preparing a solution II; 3, adding the solution I to the solution II at a stirring state, completely stirring, adjusting the pH value of the mixed solution to 6-9 to obtain the suspension composition. According to the present invention, the suspension composition provided by the present invention has characteristics of good uniformity and strong stability, is not easy to agglomerate when the suspension composition is placed for a long time; the preparation method has characteristics of simple process and low production cost; the suspension composition can be applicable for treating the oral mucositis caused by the chemoradiotherapy, and severe mouth ulcers caused by anaerobic bacteria; the suspension composition provides effects of analgesia, inflammation eliminating and mucosa repairing; the clinical efficacy of the suspension composition is obvious; the use of the suspension composition is convenient and safe.

The present invention relates to a method for predicting or diagnosing outcome of concomitant chemo-radiotherapy of a subject suffering from brain tumor. The present invention further relates to compositions and methods for treatment or prevention of tumor resistance in a subject suffering from a brain tumor and to a kit useful for predicting or diagnosing the tumor resistance in a subject treated with concomitant chemo-radiotherapy.

The invention relates to an anti-cancer sustained release injection, consisting of sustained release microspheres and menstruum, wherein, the sustained release microspheres comprise sustained release auxiliary material, angiogenesis inhibitor and/or proteolytic enzyme; and the menstruum contains suspending agent. The angiogenesis inhibitor is selected from gefitinib, erlotinib, lapatinib, vatalanib, pelitinib, endostatin, imatinib, semaxanib, dasatinib, avastin, sorafenib, sunitinib, telcyta or panitumumab; the proteolytic enzyme is selected from one or the combination of collagenase, hyaluronidase, relaxin and plasmase; the sustained release auxiliary material is selected from polifeprosan, decanedioic acid copolymer, EVAc, polylactic acid, the mixture or the copolymer thereof, and the like; and the suspending agent is selected from carboxymethyl cellulose and the like with the viscosity of 100cp to 3000cp (under the temperature of 25 DEG C to 30 DEG C). The injection can also be made into a sustained release implant. The sustained release injection is injected or arranged in or around the tumour and can improve the local drug concentration selectively, reduce the general reaction of the drug, inhibit the growth of tumour cell and blood vessel and enhance the treatment effect of non-operative treatments, such as radiotherapy, chemotherapy, etc.

The invention provides an anti-cancer sustained-release agent co-carrying glucocorticoid and chemotherapeutic drugs and belongs to sustained-release injections. The anti-cancer sustained-release agent comprises sustained-release microspheres and a solvent, wherein, the sustained-release microspheres comprise anti-cancer active components and sustained-release auxiliary materials; and the solvent is a particular solvent containing a suspending agent. The glucocorticoid is selected from prednisolone, methylprednisolone, dexamethasone, betemethasone, triamcinolone acetonide or triamcinolone acetonide; the chemotherapeutic drugs are selected from phosphoinositide 3-kinase inhibitor, pyrimidine analogues and the like; the sustained-release auxiliary materials are biocompatible high-polymers, such as polylactic acid and the copolymers thereof, polyethylene glycol, carboxyl-terminated polylactic acid copolymers, polyfatty acid dimer-sebacic acid copolymers, poly(erucic acid dimer-sebacic acid), poly(fumaric-co-sebacic acid), polifeprosan and the like; and the suspending agent with the viscosity being 100cp to 3,000cp (at the temperature of 20 to 30 DEG C) is selected from sodium carboxymethyl cellulose and the like. The anti-cancer active components and the sustained-release microspheres can further be prepared into sustained-release implants which can effectively inhibit the growth of tumors, alleviate edema and improve the curative effects of radiotherapy and chemotherapy by intra-tumor or peri-tumor injection or placement.

The invention relates to a preparation of traditional Chinese medicine decoction pieces, and particularly relates to a leukocyte-increasing traditional Chinese medicine decoction piece combined preparation as well as a preparation method and a combined package thereof. The preparation is prepared from the following raw materials in parts by weight: 10-15 parts of epimedium, 10-15 parts of fructus psoraleae, 5-10 parts of radix aconiti carmichaeli, 5-10 parts of fructus lycii, 5-10 parts of astragalus membranaceus, 3-8 parts of suberect spatholobus stem, 3-5 parts of rubia cordifolia, 3-5 parts of angelica sinensis, 1-3 parts of rhizoma phragmitis, 1-3 parts of radix ophiopogonis and 1-3 parts of licorice root. The preparation has the effects of warming kidneys and strengthening spleen, tonifying qi and blood, is used for treating patients with leukocytopenia due to spleen-kidney yang deficiency and qi-blood deficiency caused by cancer radiotherapy and chemotherapy, wherein leukocytopenia due to spleen-kidney yang deficiency and qi-blood deficiency has the syndromes of exhaust and fatigue, lack of energy, extreme chilliness, poor appetite and loose stool, soreness and weakness of waist and knees and the like. The preparation is capable of effectively increasing the content of leukocyte in blood, reducing the toxic and side effect of chemotherapy, and effectively improving the living quality of tumor patients.

The invention belongs to the technical field of medical treatment and pyradiomics, and particularly relates to a gene heterogeneity visual quantification method in glioma based on pyradiomics and a system. The method of the invention comprises the steps of segmenting a glioma magnetic resonance image by means of an image segmenting network 3D U-net; performing predictive modeling on the integral glioma IDH (isocitrate dehydrogenase), namely performing high-flux characteristic extraction and characteristic screening on the image, and screening a characteristic combination which is most sensitive and most effective to gene expression; performing heterogeneous modeling on the glioma IDH based on an image block, extracting a multi-dimensional data block of the glioma image, obtaining the IDH expression strength of each data block based on the integral predicting model; and finally forming the IDH distribution visualization and quantitative expression of the whole tumor. The method and thesystem have advantages of more accurately determining the prognosis and radiotherapy and chemotherapy sensitivity of the patient, realizing surgery resection and targeting treatment in heterogeneous atlas navigation, and realizing high clinical value in improving treatment effect of the patient and improving survival prognosis.